21st Century Cures Act Moves Through House with Funding for FDA, Cancer Moonshot

KATIE KOSKO
Thursday, December 01, 2016
Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
21st Century Cures Act Moves Through House with Funding for FDA, Cancer Moonshot
The United States House of Representatives has voted 392-26 to pass the 21st Century Cures Act.

The bill, which underwent 2 years of negotiations, gives more than $6 billion for cutting-edge health initiatives, including an allocated $1.8 billion to support Vice President Joe Biden’s Cancer Moonshot program.

Fred Upton, Sixth Congressional District of Michigan, chairman of the House Energy Commerce Committee spearheaded the initiative with the help of Democrat Diana DeGette, First Congressional District of Colorado.

In a statement, the co-authors called the bill “the innovation game-changer that patients, their loved ones and the nation’s researchers and scientists so desperately need.”

In addition to funding for the Moonshot initiative, the 21st Century Cures Act also allocated $1 billion to fighting the opioid epidemic; $1.5 billion for the BRAIN Initiative that finds new ways to treat, cure and prevent brain disorders such as Alzheimer’s and epilepsy; $1.5 billion over 10 years for the Precision Medicine Initiative; and $500 million to the U.S. Food and Drug Administration (FDA) over 10 years to speed up the drug approval process and access to medical devices for patients. It also includes bipartisan mental health reforms.

The president of the American Society of Clinical Oncology (ASCO), Daniel Hayes, MD, praised the House for the passage of the bill.

“The U.S. House of Representatives took a significant step forward to accelerate the pace of bringing promising new treatments to patients – including the 1.6 million Americans diagnosed with cancer each year,” Hayes said in a statement.

“ASCO is particularly pleased that the bill takes a step forward in addressing the interoperability of electronic health records (EHRs) and that the legislation puts restrictions on intentional information blocking,” he added. “These much-needed improvements will make it easier to coordinate patient care across a variety of medical providers – and advance important efforts on big data and precision medicine.”

While the bill cleared the House, it has not come without controversy surrounding some components of the legislation regarding the FDA. Some patient advocates worry that safety will be sacrificed in the rush to push drugs to the markets.

In a press release, The White House urged the Senate to pass the bill. However, the vote, which is set for early next week in the Senate, may not come without a battle.

Elizabeth Warren, US senator from Massachusetts, called the bill “extortion,” and added that the legislation had been “hijacked” by the pharmaceutical industry. She vowed to fight it if it reached the Senate.

Democrat Frank Pallone, Jr, Sixth Congressional District of New Jersey also worked to help advance this legislation. In an interview with CURE last year, Pallone, Jr explained the impetus for the 21st Century Cures Act came from advocacy groups who visit him both locally and in Washington, DC.

“They usually say that they would like to see some innovative program, so that there is more money for research or expedited approval,” said Pallone, Jr.

On the House floor, Pallone, Jr, said, “This is not a perfect bill, but after much consideration I believe the benefits outweigh my concerns and I support its passage.”

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.